Market closedNon-fractional

Erasca/ERAS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Erasca

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Ticker

ERAS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

126

Erasca Metrics

BasicAdvanced
$594M
Market cap
-
P/E ratio
-$0.84
EPS
1.06
Beta
-
Dividend rate
$594M
1.06
10.139
9.872
17.618
19.048
-21.39%
-37.60%
1.14
1.14
-3.02
-54.45%
-42.71%

What the Analysts think about Erasca

Analyst Ratings

Majority rating from 9 analysts.
Buy

Erasca Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$35M
17.85%
Profit margin
0.00%
NaN%

Erasca Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.43%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.21
-$0.20
-$0.20
-$0.23
-
Expected
-$0.24
-$0.22
-$0.23
-$0.20
-$0.18
Surprise
-11.02%
-9.09%
-11.95%
14.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Erasca stock?

Erasca (ERAS) has a market cap of $594M as of July 05, 2024.

What is the P/E ratio for Erasca stock?

The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of July 05, 2024.

Does Erasca stock pay dividends?

No, Erasca (ERAS) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Erasca dividend payment date?

Erasca (ERAS) stock does not pay dividends to its shareholders.

What is the beta indicator for Erasca?

Erasca (ERAS) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Erasca stock

Buy or sell Erasca stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing